The DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.
European S2k Guideline on Chronic Pruritus
Open accessAbstract
Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases chronic pruritus may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of chronic pruritus comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating chronic pruritus needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. We present the updated and consensus based (S2k) European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“• Dupilimab (515) (300 mg/weekly or/2 weeks)”
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationOmalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215372 · Cited by 1,105
The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use
LEWIS-JONES, M. S., & FINLAY, A. Y. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb16953.x · Cited by 1,051
Systematic review of treatments for atopic eczema.
Hoare, Po, L. W., & Williams (2000) · Health Technology Assessment · doi:10.3310/hta4370 · Cited by 794
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
Ständer, S., Weisshaar, E., Mettang, T., Szepietowski, J., Carstens, E., Ikoma, A., Bergasa, N., Gieler, U., Misery, L., Wallengren, J., et al. (2007) · Acta Dermato-Venereologica · doi:10.2340/00015555-0305 · Cited by 763
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Self-citationPapp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Extrahepatic manifestations of chronic hepatitis C
Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Charles Piette, J., Opolon, P., & for the MULTIVIRC GROUP (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199910)42:10<2204::aid-anr24>3.0.co;2-d · Cited by 648
Cited by
Yosipovitch, G., & Bernhard, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1208814 · Cited by 405
Ständer, S., & Luger, T. A. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-44605-8_14 · Cited by 67
Self-citationPsychosomatic and psychiatric disorders and psychologic factors in pruritus
Stumpf, A., Schneider, G., & Ständer, S. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.08.015 · Cited by 43
Self-citationPatients with Chronic Urticaria Remain Largely Undertreated: Results from the DERMLINE Online Survey
Wagner, N., Zink, A., Hell, K., Reinhardt, M., Romer, K., Hillmann, E., Baeumer, D., & Schielein, M. C. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00537-5 · Cited by 41
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1638910 · Cited by 26
Self-citation
Metadata
- Authors
- Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., Şavk, E., Streit, M., Tschachler, E., Wallengren, J., & Ständer, S.
- Venue
- Acta Dermato Venereologica
- Published
- 2019
- Volume
- 99
- Issue
- 5
- Pages
- 469-506
- ISSN
- 0001-5555 (ISSN-L)
- OpenAlex
- W2985069633
- Cited by
- 405
- References
- 295
- FWCI
- 31.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European S2k Guideline on Chronic Pruritus. https://app.cochat.ai/papers/10.2340/00015555-3164
- The paper
- Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., Şavk, E., Streit, M., Tschachler, E., Wallengren, J., & Ständer, S. (2019). European S2k Guideline on Chronic Pruritus. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-3164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.